이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Puma Biotechnology 배당금

배당금 기준 확인 0/6

Puma Biotechnology 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	US$0.32
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 PBYI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: PBYI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Puma Biotechnology 시장 대비 배당 수익률

PBYI 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (PBYI)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (PBYI)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PBYI 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PBYI 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PBYI 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: PBYI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Puma Biotechnology 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)

Investor sentiment deteriorates as stock falls 20%

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Puma Biotechnology, Inc., Annual General Meeting, Jun 18, 2024

Puma Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment deteriorates as stock falls 15%

Consensus EPS estimates increase by 45%, revenue downgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Puma Biotechnology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Founder notifies of intention to sell stock

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment improves as stock rises 15%

Independent Director recently sold US$71k worth of stock

Independent Director notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Puma Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 32%, revenue downgraded

Investor sentiment improves as stock rises 17%

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Consensus EPS estimates increase by 240%

Full year 2022 earnings released: EPS: US$0 (vs US$0.72 loss in FY 2021)

Puma Biotechnology, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Puma Biotechnology, Inc.’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

Founder recently sold US$114k worth of stock

Founder notifies of intention to sell stock

Investor sentiment deteriorated over the past week

Puma Biotechnology, Inc. announced that it has received $2.499996 million in funding

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium

Investor sentiment improved over the past week

Price target decreased to US$5.40

Puma Biotechnology, Inc. Announces Update on Defamation Lawsuit

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Consensus forecasts updated

Puma Biotechnology, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Consensus forecasts updated

Independent Director recently sold US$89k worth of stock